Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Uǧur Șahin establishes scientific department at HI-TRON Mainz

No. 14 | 15/03/2022 | by Koh

The immunologist, cancer researcher and entrepreneur Uǧur Șahin is establishing a scientific department for mRNA-based cancer immunotherapy at the Helmholtz Institute "HI-TRON Mainz". In HI-TRON Mainz, the German Cancer Research Center (DKFZ), the TRON gGmbH as a subsidiary of the University Medical Center Mainz, the University Medical Center Mainz and the Johannes Gutenberg University Mainz cooperate. The aim of the partnership is to develop effective immunotherapies, identify new biomarkers for the treatment of tumor diseases and thus further advance personalized cancer therapy.

Uǧur Șahin
© Wikipedia/Raimond Spekking

The compelling idea behind the concept of mRNA-based cancer immunotherapies: Messenger RNA molecules (mRNA) are used to get the body to produce its own tumor proteins that stimulate the immune system to fight the cancer. The great advantage of this approach is that it makes it comparatively easy and fast to produce highly individualized tumor vaccines. To do this, scientists first search the tumor genome of individual patients for mutations that distinguish cancer cells from healthy cells and that are possible targets for a therapeutic vaccine. The appropriate mRNA molecules containing these mutations are then produced in the laboratory and can be used as an individual therapeutic cancer vaccine.

Uǧur Șahin is one of the world's most important pioneers in this research field. The professor of translational oncology and immunology at the University Medical Center Mainz and co-founder of BioNTech AG has already conducted early clinical trials on the efficacy of personalized mRNA vaccines against cancer. But there is still an immense need for research: Which target structures are suitable, which types of cancer can be treated with this therapy, how can cancer cells be prevented from evading immune attack? And is mRNA vaccination sufficient as a therapy or must it be combined with other treatments? These are just some of the questions that the researchers in Șahin's department, which was established on February 1 at the DKFZ as the sponsor of HI-TRON Mainz, intend to address.

In the Helmholtz Institute for Translational Oncology Mainz (HI-TRON Mainz), the German Cancer Research Center (DKFZ) cooperates with the Research Institute for Translational Oncology at the University Medical Center of the Johannes Gutenberg University Mainz (TRON gGmbH), the University Medical Center Mainz and the Johannes Gutenberg University Mainz to bring together the partners' internationally outstanding expertise in the field of personalized immunotherapy with cutting-edge translational research at DKFZ. The mission of HI-TRON Mainz is to build on the expertise and know-how of the partners to exploit the potential of individualized immunotherapy for the benefit of cancer patients. The strategic goal is also to position Germany in the leading international league in this innovative and relevant field.

With the Helmholtz Institutes, the Helmholtz Association creates the basis for a lasting close collaboration between a Helmholtz Center, in this case the DKFZ, and a university in a field of research that is of particular importance to both partners.

With more than 3,000 employees, the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is Germany’s largest biomedical research institute. DKFZ scientists identify cancer risk factors, investigate how cancer progresses and develop new cancer prevention strategies. They are also developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to questions relating to cancer.

To transfer promising approaches from cancer research to the clinic and thus improve the prognosis of cancer patients, the DKFZ cooperates with excellent research institutions and university hospitals throughout Germany:

  • National Center for Tumor Diseases (NCT, 6 sites)
  • German Cancer Consortium (DKTK, 8 sites)
  • Hopp Children's Cancer Center (KiTZ) Heidelberg
  • Helmholtz Institute for Translational Oncology (HI-TRON Mainz) - A Helmholtz Institute of the DKFZ
  • DKFZ-Hector Cancer Institute at the University Medical Center Mannheim
  • National Cancer Prevention Center (jointly with German Cancer Aid)
The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.


Subscribe to our RSS-Feed.

to top
powered by webEdition CMS